Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04519567 · ClinicalTrials.gov registry record · Phase 1
Multiple Ascending Dose Study of CTI-1601 Versus Placebo in Subjects With Friedreich's Ataxia
A Phase 1 study, sponsored by Larimar Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 27
- Enrollment target
NCT04519567 is a Phase 1 study that has completed, run by Larimar Therapeutics. The registered enrollment target is 27 participants.
The verdict
NCT04519567, a Phase 1 study, has completed, sponsored by Larimar Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 27 participants
- Enrollment target
Study Summary
To evaluate the safety and tolerability of multiple ascending doses of CTI-1601 in participants with Friedreich's ataxia
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL CTI-1601
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2020-07-31 |
| Est. Completion | 2021-03-16 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04519567
The ClinicalTrials.gov registry entry for NCT04519567 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Larimar Therapeutics, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04519567 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04519567 about?
NCT04519567 is a clinical study titled "Multiple Ascending Dose Study of CTI-1601 Versus Placebo in Subjects With Friedreich's Ataxia". To evaluate the safety and tolerability of multiple ascending doses of CTI-1601 in participants with Friedreich's ataxia
What is the current status of trial NCT04519567?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 2020-07-31. Estimated completion is 2021-03-16.
What interventions are being tested in trial NCT04519567?
The interventions under investigation include: Placebo (BIOLOGICAL), CTI-1601 (BIOLOGICAL).
Who is sponsoring clinical trial NCT04519567?
This trial is sponsored by Larimar Therapeutics, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.